Form 4: OptimizeRx CFO/COO Receives Significant Equity Grants

Edward Stelmakh, CFO/COO of OptimizeRx Corp, was granted 15,625 restricted stock units and options for 35,156 shares of common stock.

Summary

• Edward Stelmakh, the Chief Financial Officer and Chief Operating Officer of OptimizeRx Corp (OPRX), was granted equity awards on August 21, 2025.
• The grants include 15,625 shares of common stock in the form of restricted stock units (RSUs) at a price of $0 per share.
• These RSUs will vest in three equal annual installments, with the first vesting occurring on August 21, 2026.
• Additionally, Mr. Stelmakh was granted stock options for 35,156 shares of common stock with an exercise price of $16.14 per share.
• The stock options also vest in three equal annual installments, beginning on August 21, 2026, and have an expiration date of August 21, 2030.
• Following these transactions, Mr. Stelmakh beneficially owns 110,764 shares of common stock directly and 35,156 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: The grant of equity awards to a key executive is a positive sign of management retention and alignment with shareholder interests, though it does not reflect operational performance or new strategic initiatives.

Positives

• The grant of restricted stock units and stock options to a key executive like the CFO/COO aligns management's long-term interests with those of shareholders.
• Equity compensation is a standard practice for retaining and incentivizing senior leadership, potentially contributing to stable management.

Future Outlook

The restricted stock units and stock options are structured to vest over three equal annual installments, beginning on August 21, 2026, indicating a long-term incentive structure for the executive.

Industry Context

Equity grants to senior executives are a common practice across industries, particularly in technology and healthcare sectors like OptimizeRx, to align management incentives with long-term shareholder value creation and to ensure executive retention.

Comparison to Industry Standards

• The structure of equity grants, including restricted stock units and stock options with multi-year vesting schedules, is consistent with typical executive compensation practices observed in publicly traded companies within the healthcare technology sector.
• The use of a Rule 10b5-1(c) plan for these transactions is a standard corporate governance measure to provide an affirmative defense against insider trading allegations.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity grants align the interests of the CFO/COO with long-term shareholder value creation, potentially leading to more focused management decisions aimed at increasing stock price.
• Employees: Executive compensation practices can influence overall company morale and compensation strategies.

Next Steps

• The restricted stock units and stock options will begin to vest in three equal annual installments starting August 21, 2026.

Key Dates

Recommendation

This Form 4 filing details routine equity compensation for a key executive, which is a standard practice to align management incentives with long-term shareholder value. It does not provide new information regarding the company's operational performance or strategic direction that would warrant a change in investment recommendation based solely on this filing.

Keywords

OptimizeRx, OPRX, Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, Stock Options, CFO/COO, Edward Stelmakh, Executive Compensation